Stockreport

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yaho...

Xenetic Biosciences, Inc.  (XBIO) 
NASDAQ:AMEX Investor Relations: ir.xeneticbio.com
PDF Results bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FR [Read more]